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Severe viral lower respiratory infections are a major cause of infant morbidity. In develop-
ing countries, respiratory syncytial virus (RSV)-bronchiolitis induces significant mortality, 
whereas in developed nations the disease represents a major risk factor for subsequent 
asthma. Susceptibility to severe RSV-bronchiolitis is governed by gene–environmental 
interactions that affect the host response to RSV infection. Emerging evidence suggests 
that the excessive inflammatory response and ensuing immunopathology, typically as a 
consequence of insufficient immunoregulation, leads to long-term changes in immune cells 
and structural cells that render the host susceptible to subsequent environmental incur-
sions. Thus, the initial host response to RSV may represent a tipping point in the balance 
between long-term respiratory health or chronic disease (e.g., asthma). The composition 
and diversity of the microbiota, which in humans stabilizes in the first year of life, critically 
affects the development and function of the immune system. Hence, perturbations to 
the maternal and/or infant microbiota are likely to have a profound impact on the host 
response to RSV and susceptibility to childhood asthma. Here, we review recent insights 
describing the effects of the microbiota on immune system homeostasis and respiratory 
disease and discuss the environmental factors that promote microbial dysbiosis in infancy. 
Ultimately, this knowledge will be harnessed for the prevention and treatment of severe viral 
bronchiolitis as a strategy to prevent the onset and development of asthma.
Keywords: viral lower respiratory tract infection, RSv, asthma, microbiome, microbiota, microbiota and 
immunity, PvM
iNTRODUCTiON
Viral lower respiratory infections (vLRI) caused by respiratory syncytial virus (RSV) are a major 
cause of morbidity and mortality in young infants. In developed countries, epidemiological studies 
have reproducibly implicated RSV-bronchiolitis as a major risk factor for the onset and progression of 
asthma [reviewed extensively in Ref. (1)]. The immunopathology associated with RSV-bronchiolitis 
in early-life may lead to long-lived alterations to airway structural and/or resident immune cells 
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that render the host susceptible toward allergic sensitization 
and asthma (2–4). Susceptibility to both RSV-bronchiolitis and 
asthma has been attributed to defects in immunoregulatory and 
antiviral pathways, the cause of which may be genetic and/or 
environmental (1, 2, 5, 6). Interestingly, rates of RSV-bronchiolitis 
peak at 2–6 months of age (7, 8), whereas asthma typically begins 
to develop later in childhood (2), highlighting a window of sus-
ceptibility to RSV in early-life, which, if engaged, may leave the 
host vulnerable to asthma development. Hence, factors that influ-
ence the development and/or function of the immune system may 
critically impact the host response to RSV. It is now recognized 
that the composition and diversity of the microbiota, which sta-
bilizes around 12 months of age in humans (9–13), fundamentally 
affects host physiology and immunity (12, 14–19). Several recent 
studies have demonstrated changes in the respiratory microbi-
ome in subjects with RSV-bronchiolitis (20–23). Similar observa-
tions have been reported in asthma (24–28). Whether microbial 
dysbiosis—changes in the composition of the gut and/or lung 
microbiota—predisposes to RSV-bronchiolitis and asthma or is 
simply a consequence of disease remains unclear. In this review, 
we discuss recent clinical and experimental findings implicating 
a role for the microbiota in infant respiratory health and disease. 
We also consider how this knowledge might be harnessed for the 
prevention and treatment of severe bronchiolitis as a strategy to 
curtail the short- and long-term burden of disease, with a specific 
emphasis on the onset and development of asthma.
THe LiNK BeTweeN SeveRe OR 
FReQUeNT vLRi AND SUBSeQUeNT 
ASTHMA DeveLOPMeNT
Numerous birth cohort studies have assessed the association 
between vLRIs in early-life and asthma risk (29–46). Although 
this association is moderate for certain viruses [e.g., influenza 
(47) and human metapneumovirus (44, 48–50)], the association 
is much stronger for RSV and rhinovirus (RV) (29–42). This 
relationship also appears to extend to allergic sensitization, but 
whereas severe RSV vLRIs appear to precede allergic sensitiza-
tion this is less common for RV; rather allergic sensitization is a 
precursor to severe RV vLRIs (51, 52). A recent study evaluating 
two large cohorts of infants (>80,000 and >180,000) found that 
the population-attributable risk for asthma contributed by infant 
bronchiolitis during the RSV season was 10 and 13%. However, 
in the subset of children with infant RSV-bronchiolitis, the 
attributable risk was 49 and 47% (41). The relationship between 
RSV disease severity and subsequent asthma inception is dose-
dependent lending support to a causal relationship (42, 52, 53). 
In further support of this notion, RSV-immunoprophylaxis 
is effective in reducing rates of recurrent wheeze and asthma 
(54–56). However, because all humans have been infected with 
RSV by the age of 3 and the population at large is not asthmatic, 
other co-factors (e.g., genetic and/or environmental) likely col-
lude with RSV, to increase the risk of bronchiolitis in infancy. 
Thus the asthma-prone phenotype is likely established early in 
life and progresses to persistent disease following subsequent 
rounds of allergen and/or viral exposure (2). Using a high-fidelity 
mouse model, we have demonstrated that defects in plasmacytoid 
dendritic cells (pDCs) or toll-like receptor (TLR) 7/interferon 
regulatory factor (IRF) 7 signaling predisposes to severe viral 
bronchiolitis and subsequent asthma (57–61). In this scenario, 
the impaired immune response may lead to enhanced epithelial 
injury and secondary tissue repair leading to long-lived changes 
to the epithelium (genetic or epigenetic). In turn, this may 
promote the development of Th2 immunity by modulating the 
underlying network of DCs and innate lymphoid cells (ILCs). 
We and others have shown that house dust mite (HDM)-induced 
epithelial-derived IL-1α and high-mobility group box (HMGB) 1 
act in a cytokine cascade and in feed-forward loops to induce the 
production of Th2-instructive cytokines, such as IL-33, thymic 
stromal lymphopoietin, IL-25, and granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which license local DCs 
and type 2 ILC to promote Th2 immunity (62–64). Hence, epi-
thelial stress as a consequence of allergen exposure or respiratory 
viral infection-associated cytopathology in predisposed indi-
viduals leads to the release of tissue alarmins—IL-1α, HMGB1, 
and IL-33—to promote a cytokine microenvironment that is 
conducive to the generation of Th2 immunity. In addition to 
providing pro-type 2 inflammatory signals, these cytokines also 
act by inhibiting pro-type I inflammatory signals. For example, 
allergen-induced IL-33 amplifies the allergic response in part by 
inhibiting CD11b+ DCs (DC2) IL-12p35 production (65). IL-33 
can also suppress the production of interferon alpha, suppressing 
its negative regulatory effects on type 2 immunity (59, 66).
The teleological role of Th2 immunity is to initiate tissue 
repair; however, following repeated environmental insult(s) 
throughout life, type 2 inflammation may lead to pathologic 
tissue remodeling (67–69). Once established, this inflammatory 
response is maintained by both structural cells [e.g., airway epi-
thelial cells (AECs), endothelial cells, and airway smooth muscle 
cells] and immune cells (e.g., type 2 ILCs, DCs, macrophages, and 
T helper cell subsets), which act in concert to produce an array 
of pro-inflammatory lipids, cytokines, and chemokines [recently 
reviewed in Ref. (4)]. The relative importance of type 2 ILCs and 
CD4+ Th2 in this process has been the subject of much interest 
and debate in the field with recent studies implicating type 2 ILCs 
in antigen presentation (70) and potentiating memory CD4+ Th2 
cells (via IL-13-dependent licensing of DCs) (64). Intriguingly, 
“innate” CD4+ Th2 cells have been proposed. This novel cell sub-
set can be primed locally in the lung by Th2-instructive cytokines, 
together with an activator of the signal transducer and activator 
of transcription 1 family of transcription factors, in the absence 
of antigen presentation (71).
Now, that a number of type 2 instructive cytokines have 
been identified, this has opened up opportunities to halt the 
progression and/or decrease the severity of asthma through 
the use of humanized monoclonal antibodies. Additionally, a 
better understanding of the factors that confer susceptibility to 
bronchiolitis and its nexus with asthma onset, may yield new 
opportunities for targeted intervention. Critically, this raises the 
possibility of primary prevention. Emerging evidence discussed 
in this review highlights the supportive influence of the micro-
biome on the maturing immune system. Thus perturbations 
to the microbiome, occurring prenatally or postnatally, could 
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adversely affect host defense against RSV, and this might lead to 
long-term alterations as a consequence of aberrant programming 
(genetic or epigenetic) of structural and/or immune cells. In this 
paradigm, further exposure of these susceptible individuals to 
environmental triggers of asthma (e.g., allergen and/or viral 
infection) in later-life may progress the asthma-prone phenotype 
to established and persistent disease.
THe AiRwAY BACTeRiAL MiCROBiOTA iS 
DYSBiOTiC iN ASTHMA, BUT wHY?
For centuries, the lower airways have been considered a sterile 
environment, a dogma based primarily on culture-based studies 
in which any culturable microbes from bronchoalveolar lavage 
(BAL) samples were considered to be contamination or of little 
clinical significance (72). In fact, the lung harbors an abundant 
and diverse microbial community (a microbiota) that is highly 
dynamic and underpinned by the immigration and emigration 
of microbes with every breath of air (approximately 7,000 L/day) 
and the occasional subclinical aspiration of the oropharyngeal 
contents (73–75). Culture-independent techniques involving 
high-throughput sequencing of the 16S rRNA gene, a highly 
conserved locus of the bacterial genome, has led to a revolution 
in our understanding of the airway microbiome. Using this 
approach, investigators have begun to probe the human airways 
in health and disease, and pioneering studies have revealed 
that the microbial community inhabiting the lower airways of 
asthmatics is indeed quite different from that of healthy subjects 
(25, 26, 28). Whether the asthmatic airways are more highly 
populated (i.e., grater bacterial load) remains unclear with some 
studies finding increases in abundance (25) and others report-
ing no difference compared to control (26). Several studies 
report that the airway microbiota, sampled by BAL (26, 76) or 
nasal swab (28), of mild-to-moderate asthmatics is enriched in 
members of the Gram-negative bacterial phylum Proteobacteria 
including the potential pathogens Haemophilis, Moraxella, and 
Neisseria (26, 28, 76) and reduced in the commensal phylum 
Bacteroidetes (28, 76). However, this profile appears to differ 
somewhat according to the inflammatory phenotype and/or 
severity status, as well as corticosteroid treatment (27). For 
example, in a study directly comparing the sputum microbiota 
in severe and non-severe asthma, Zhang and colleagues found 
that mild-to-moderate and, to a lesser extent, severe disease 
was associated with increased Proteobacteria, while both severe 
and non-severe asthmatic individuals had a lower abundance 
of Bacteroidetes (particularly Prevotella spp.) and Fusobacteria 
(76). Moreover, a greater abundance of Streptococcus spp., 
which are affiliated with the phylum Firmicutes, was uniquely 
associated with severe asthma. In this study, severe asthma was 
associated with blood and sputum eosinophilia, but not neu-
trophilia. Green et al. found that sputum neutrophilia and IL-8 
levels directly correlated with the abundance of Streptococcus 
spp, as well as Haemophilus and Moraxella in severe asthmatics 
(77), while Goleva and colleagues reported that Haemophilus 
parainfluenzae was uniquely present in the airways of 
corticosteroid-resistant asthmatics (26). Additionally, a study 
comparing the sputum microbiome in chronic and persistent/
severe asthmatics found reduced bacterial diversity combined 
with a high prevalence of Haemophilus influenzae in asthmat-
ics with neutrophilic inflammation, whereas asthmatics with 
eosinophilic inflammation had abundant Tropheryma whipplei 
(78). One interpretation of these data is that disease severity and 
possibly the inflammatory profile or asthma phenotype relate to 
the composition or dysbiosis of the airway microbiota. Further 
work is needed to determine whether the presence or absence 
of certain microbial communities underpins different asthma 
phenotypes or whether these changes are secondary to the 
pathological environment characteristic of the asthma subtype. 
Whereas several studies have examined the lung microbiota in 
stable asthma, very few have examined the microbiota during 
acute exacerbation(s) of asthma. This is surprising, since 80% of 
asthma exacerbations are attributed to a viral infection (34, 79), 
predominantly a species of RV, which likely affects or is affected 
by the bacterial community of the airways. An interesting study 
in which healthy adult subjects were experimentally infected 
with RV revealed increases in the relative abundances of upper 
airway H. parainfluenzae and Neisseria subflava following 
infection (80), two potentially pathogenic bacterial species 
reported to be present in the lower airways in asthma. Whether 
the upper airway microbiota reflects the lower airways remains 
an unresolved question, but these findings do highlight a shift 
toward an asthma-like microbiota caused by RV infection, 
which may impact the mechanism by which RV causes asthma 
exacerbations. In an attempt to address this issue, Kloepfer 
et al. studied a population of 308 school-age children, half with 
asthma and half healthy controls using PCR-based analysis of 
nasal secretions for a period of 5  weeks during autumn over 
2 consecutive years (81). The authors found that the presence 
and abundance of either Moraxella catarrhalis or Streptococcus 
pneumoniae at the time of RV infection was positively associ-
ated with the severity of RV-associated exacerbations. The 
authors speculated that the viral infection/exacerbation could 
lead to a lung environment that is conducive to colonization 
with potential pathogens.
In summary, it is evident that lung microbial dysbiosis 
represents a component of the asthmatic syndrome; however, 
the nature of this dysbiosis and its relationship to asthma 
phenotype(s) remain ill-defined and needs further investigation. 
More importantly, it remains an open question as to whether 
microbial dysbiosis precedes and is causal for asthma onset or 
simply develops as a consequence of the dysregulated lung envi-
ronment. In this regard, we must consider the early-life origins 
of asthma.
AiRwAY MiCROBiAL DYSBiOSiS AND THe 
RSv-BRONCHiOLiTiS TO ASTHMA NeXUS
The notion that asthma risk may be influenced by inappropri-
ate colonization by microbes stems from the seminal findings 
of the Copenhagen Birth Cohort Study (82). Using culture-
dependent profiling, this study was the first to uncover the 
presence of potentially pathogenic species in the oropharynx 
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of 1-month-old infants significantly at risk of developing 
asthma in later childhood. Pathogenic species detected in 
these subjects included M. catarrhalis, H. influenzae, or S. 
pneumoniae. Additional studies by this group that showed 
these same bacterial species were present during periods of epi-
sodic wheeze caused by infection with a respiratory virus (83). 
These paradigm-shifting studies implicated colonization of the 
airways by opportunistic pathogens in the inception of asthma. 
Whether these bacterial species are causative for later asthma is 
not yet clear and remains a hotly debated subject (84–86). Some 
investigators argue that if pathogenic bacteria were causative 
then antibiotic therapies should reduce wheezy episodes and 
decrease asthma risk, but meta-analyses of population cohort 
studies suggest they do not (85–87). However, this interpreta-
tion is oversimplified since antibiotic treatment also ablates 
bacteria that are beneficial, for example those species which 
generate metabolites that promote the differentiation of regula-
tory T (Treg) cells (discussed later in more detail). Modern 16S 
RNA gene sequencing has revolutionized this area of research 
and continues to provide new insights. Recent studies armed 
with this technology have begun analyzing airway and gastro-
intestinal samples from birth cohort studies (22, 23, 88). Such 
analyses have also attempted to address important questions 
surrounding which bacterial species first colonize the airways 
and whether this differs in settings of acute respiratory illness 
and asthma risk. For example, an elegant study by Teo et  al. 
sought to address this gap in knowledge in a recent study of 
children enrolled in the Childhood Asthma Study (22). In this 
study, nasopharangeal aspirates were collected from subjects 
during planned visits at 2, 6, and 12 months of age and within 
48 h from the onset of an acute respiratory infection. This high 
intensity sampling regimen allowed the authors to temporally 
assess changes in the nasopharangeal microbiota and the 
relationship between upper airway colonization and chronic 
wheeze outcome at age 5. They found that Staphylococcus and 
Corynebacterium, common components of the human skin 
microbiome, were the dominant bacterial species present in 
the first 2 months of life before switching to either Alloiococcus 
or Moraxella at 6–12 months, concomitant with a stabilization 
of the microbiome. Because of the presence of species typically 
found on the skin, the authors speculated that infants are likely 
to be colonized initially with skin-dwelling bacteria from their 
parents and others, and that these founder populations are 
replaced over time by Moraxella or Alloiococcus. This upper 
respiratory microbiota then remains stable over time in healthy 
individuals. However, in infants suffering from virus-associated 
acute respiratory infection(s), a greater abundance of potential 
pathogens Streptococcus, Moraxella, and Haemophilus was 
observed, verifying earlier findings (82). Interestingly, when 
examining upper and lower respiratory infections separately, 
the authors found that early Moraxella colonization was 
associated with younger age of first upper respiratory infec-
tion, whereas early Streptococcus colonization was associated 
with earlier initial lower respiratory infection. Additionally, 
the level of subsequent asthma risk in these infants appeared 
to relate inversely with the age at initial Streptococcus colo-
nization, leading the authors to speculate that tissue damage 
mediated by Streptococcus and/or infection with RSV/RV 
during this early-life period might have long-term effects that 
predispose to later asthma. A recent study in mice found that 
infection of 1-week-old neonates with a non-lethal dose of S. 
pneumoniae (D39) followed by aluminum hydroxide (alum)/
ovalbumin (OVA) administration and OVA challenge in adult-
hood led to Th17 type inflammation, neutrophilia, and airway 
hyperreactivity (AHR) (89). Type 2 inflammation was also 
observed but did not correlate with increased AHR or gross 
lung pathology in co-exposed mice. Rather, the exaggerated 
Th17 phenotype was associated with impaired accrual of lung 
FoxP3+ Treg cells which typically suppress pathogenic effector 
T cell driven inflammation, including that mediated by Th17 
cells. The function of these Treg cells was not assessed in this 
study and the nature of this altered immune response and tissue 
damage remains unclear. Nevertheless, these data suggest that 
S. pneumoniae exposure in early-life may act to dampen Treg 
cell responses, rendering the host susceptible to allergic airway 
inflammation. Because reduced numbers of Tregs have been 
observed in infants with RSV-bronchiolitis (90), and animal 
models have revealed a crucial role for these cells in regulating 
the inflammatory response to RSV (91), one possibility is that 
early colonization of the respiratory tract with S. pneumoniae 
dampens Treg cell responses thereby enhancing the severity of 
RSV disease, and in turn predisposing to allergic sensitization 
and asthma.
Notably, the study by Teo et al. also found that the presence of 
Moraxella was associated with increased severity of RSV infec-
tion. The relationship between RSV and Moraxella co-infection 
is an interesting one. Both virus and bacterium are more abun-
dant during cooler months, and co-infection has been associated 
with a greater incidence of otitis media (92), suggesting that 
RSV infection may alter the upper respiratory microbiome of 
the infant host in a way that is conducive to bacterial infection 
(e.g., Moraxella). A recent study by Mansbach and colleagues 
explored this idea in a prospective cohort of >1,000 infants at 
3 months of age (23). Of these infants, the major viral pathogen 
detected was RSV with a smaller proportion of subjects exhibit-
ing a co-infection with RV, and a smaller proportion still infected 
with RV alone. However, healthy controls were not included in 
this study. Comparing the nasopharyngeal microbiota of these 
three groups, the authors found a high level of Firmicutes and 
the genus Streptococcus and a low level of Proteobacteria and 
the genera Haemophilus and Moraxella in the RSV-only group, 
while the opposite was true for the RV-only group and the RSV/
RV co-infection group exhibited intermediate abundances 
of these phyla and genera. This pattern of specific virus and 
bacteria detected in the upper airways is akin to that observed 
by Teo and colleagues. However, it is not yet sufficiently clear 
whether these pathogenic bacteria contribute to disease or are 
simply reflective of opportunistic colonization/expansion in 
individuals with more severe illness. This question requires fur-
ther work using both clinical cohorts and translational animal 
models of disease. The latter will be fundamental to unraveling 
the complex interplay between host, virus and bacteria (airway 
microbiota and pathogens) and the long-term consequences for 
asthma risk.
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MiCROBiAL COLONiZATiON AND THe 
DeveLOPMeNT OF eARLY-LiFe 
ReSPiRATORY DiSeASe
Admission rates for bronchiolitis (93) and the prevalence of 
asthma and allergies have increased substantially over the past 
30 years (94–96). This has implicated a key role for environmental 
factors, most notably those associated with a “Western lifestyle.” 
Initial evidence for this was garnered from epidemiological 
studies in Europe linking decreases in family size and increased 
personal hygiene with allergic disease development and led to the 
generation of the “hygiene hypothesis” (97, 98). The central tenet 
of the hygiene hypothesis is that components of the mammalian 
immune system fail to develop appropriately or become dys-
regulated as a consequence of insufficient exposure to microbes. 
Subsequent studies of European children growing up in rural 
environments have strongly supported and extended this con-
cept. For example, Reidler et al. demonstrated in a cross-sectional 
study that children who grew up in rural farming environments 
were less likely to develop allergy and asthma and that disease 
risk was even lower if the mother had also experienced this 
microbe-rich environment during pregnancy (99). Other studies 
in farming communities have shown that high levels of lipopoly-
saccharide (LPS) in barn-dust and gastrointestinal exposure to 
unpasteurized milk are associated with tolerance to ubiquitous 
allergens and the prevention of atopy (100, 101). The protec-
tive “farm effect” on childhood asthma has been reproduced 
in several studies around the world, and a recent meta-analysis 
concluded that an overall 25% reduction in asthma risk can occur 
despite heterogeneity in the study populations (102). However, 
the strongest protection from childhood asthma was recently 
reported in Amish populations in the US, which retain traditional 
farming methods (e.g., use of horses for transportation, single-
family dairy farms) (103). By contrast Hutterites living in the US, 
with otherwise similar genetic background and lifestyle factors, 
embrace modern farming technologies (e.g., highly industrial-
ized, communal farms). Among these children, the prevalence of 
asthma in Amish compared to Hutterite school children was 5.2 
versus 21.3% and the prevalence of allergic sensitization was 7.2 
versus 33.3%. Interestingly, LPS levels were 6.8 times higher in 
Amish homes than in Hutterite homes, a finding that was associ-
ated with greater numbers of peripheral blood neutrophil which 
expressed lower levels of the activation markers (CD11b, CXCR4, 
and CD11c), lower numbers of peripheral blood eosinophils and 
lower production of the Th2-associated cytokines IL-33, IL-25, 
IL-5, and IL-4 by peripheral blood lymphocytes in the Amish 
children compared to the Hutterite children. By exposing mice to 
Amish or Hutterite house dust extracts prior to performing an i.p. 
OVA model of allergic airway inflammation, the authors showed 
that the high LPS levels of the Amish house dust conferred pro-
tection from AHR and airway eosinophilia, whereas the Hutterite 
house dust did not. As had been shown in a previous report of 
European farm children (104), the beneficial effect of house dust 
from the Amish children was associated with higher expression 
of the A20 gene (TNFAIP3) in peripheral blood lymphocytes; 
however, an increase in IRF7, a hub gene and master regulator of 
type-I IFN production, was also found in Amish children. Hence, 
it will be important to determine whether the beneficial effects of 
farm house dust exposure extend to protecting against vLRI and 
viral exacerbations of asthma.
Further evidence for the role of local microbial exposures pro-
tecting against allergic disease development in early-life comes 
from studies of microbial exposures associated with pet owner-
ship. For example, one study showed that exposure to dogs and to 
a lesser extent cats in infancy is associated with protection against 
the development of allergies in childhood, although asthma rates 
were not examined (105). Notably, environments with no house-
hold pet exhibit low levels of bacteria in the local environment 
(105–107), and thus in contrast to farm environments, these 
“microbe low” residences confer a higher risk of allergic disease 
development. Intriguingly, these homes are reported to possess a 
wider range of fungal species (108), which have long been associ-
ated with the development of asthma (109), although whether 
they shape the microbiome in early-life in a way that renders the 
host susceptible toward the development of allergies and asthma 
in later childhood remains to be determined.
These findings have fueled experimental animal studies to 
establish the mechanisms underlying the link between microbial 
exposure and protection from asthma. For example, a recent 
study by Schuijs et  al. examined the beneficial effects of barn-
dust in an acute HDM model of allergic airway inflammation in 
mice (104). In this murine model, a key initial step in the process 
of sensitization to the HDM is allergen-induced activation of 
AECs through TLR4. TLR4-signaling leads to the secretion of 
the chemokine CCL20 and GM-CSF, both of which are required 
for the recruitment and functional maturation of airway DCs. 
Consistent with the results of the European epidemiologic barn-
dust studies, Schuijs and colleagues found that airway exposure 
to LPS before or during HDM exposure markedly attenuated the 
asthma-like pattern of pro-inflammatory responses to HDM and 
reduced the activation of local DC functions mediated by CCL20 
and GM-CSF. They further demonstrated that exposure to LPS 
suppresses AEC responsiveness to TLR4-induced activation by 
HDM and that this suppression is dependent on the attenuation of 
signaling by nuclear factor κB (NF-κB). This effect was mediated 
by an increase in the synthesis of the enzyme A20, encoded by 
the Tnfaip3 gene, in AECs. Ex vivo cultures of human bronchial 
epithelial cells revealed a similar inverse association between 
LPS-mediated stimulation of GM-CSF production and activation 
of the TNFAIP3 gene. This association was further examined in a 
case–control study in which the investigators observed a relative 
deficiency in the LPS-mediated TNFAIP3 gene expression in 
AECs from asthmatic subjects as compared with healthy controls. 
Moreover, the authors observed a positive association between a 
polymorphism in the TNFAIP3 gene and susceptibility to asthma 
in the cohort of GABRIELA [Multidisciplinary Study to Identify 
the Genetic and Environmental Causes of Asthma in the European 
Community (GABRIEL) Advanced Study]. Thus, exposure to 
aerosolised bacterial components appears to regulate the thresh-
old for AEC activation, highlighting A20 expression by AECs as 
a potential therapeutic target for asthma. Although, the effects 
of A20 knockdown in AECs abrogated LPS-mediated protection 
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against the airway pathology induced by HDM, CCL20, and 
GM-CSF were not fully suppressed. This suggests the existence 
of other pathways by which LPS suppresses asthma. This apparent 
heterogeneity is not unexpected and perhaps reflects the complex 
nature of the causal pathways underlying asthma development, 
particularly in relation to other environmental stimuli.
MiCROBiOTA HYPOTHeSiS
Following birth, the infant is exposed to a diverse host and 
environmentally associated microbiota. During natural birth, 
the infant is principally colonized by a founder community of 
microbes derived from the mother’s vagina and feces (13, 110). 
Postnatally, breast milk further diversifies the neonatal micro-
biota by providing secretory immunoglobulin (Ig)A, prebiotic 
glycans (e.g., milk oligosaccharides), and other microbial 
metabolites [e.g., short-chain fatty acids (SCFAs)] (12, 111, 
112). Cesarean birth and formula feeding disturb the natural 
process of colonization. In offspring born by Cesarean section, 
the predominant bacterial populations in gut closely align with 
that of the mother’s skin (111, 113), an effect that it is further 
compounded in formula-fed infants (114). The observation that 
formula-fed infants are at greater risk of chronic inflammatory 
and metabolic diseases indicates that prebiotic- or probiotic-
supplemented infant formulas do not fully replicate the effect of 
breast milk on the development of the neonatal microbiota (115). 
This highlights that our knowledge of the factors that influence 
the emergence of the neonatal microbiota remains incomplete. 
Nevertheless, it is now appreciated that the composition of the 
intestinal microbiota is highly plastic during the early-postnatal 
period and into early childhood, changing rapidly in response 
to environmental interventions, including invasion by patho-
genic microorganisms, antibiotic treatment, and diet (116), all 
of which likely affect immune homeostasis. Thus, the hygiene 
hypothesis has now been extended to incorporate a wider array 
of environmental conditions that can perturb the microbiome, 
especially in the gastrointestinal tract. This conceptual evolution 
has led to a new theory coined the “microbiota hypothesis.” 
Studies of gnotobiotic mice [also called germ-free (GF)] mice 
have established a key role for the host microbiota in influencing 
the development and function of the immune system GF mice 
exhibit several gross physiological and functional abnormalities 
in the gastrointestinal tract including enlarged cecum, reduced 
gastrointestinal motility, and reduced production of antimicro-
bial peptides (117, 118). The absence of commensals also has 
profound effects on the development of the immune system, 
including defects in lymphoid tissue development within the 
spleen, thymus, and peripheral lymph nodes (119). Of relevance, 
an elegant study by Olszak and colleagues found that invariant 
natural killer T cells accumulate in the colonic lamina propria 
and lung in GF mice, resulting in increased morbidity in models 
of inflammatory bowel disease and allergic asthma as compared 
with that of specific pathogen-free mice (120). Notably, the 
elevated expression of the chemokine ligand CXCL16 in the 
lungs of GF mice could be normalized by conventionalization 
(introduction of GF mice to SPF conditions) but only dur-
ing the first 2  weeks of life, an effect that was dependent on 
microbiota-induced epigenetic modifications at the Cxcl16 
locus. Conventionalization after this 2-week period failed to 
rescue the asthma phenotype, highlighting a critical window of 
susceptibility during the postnatal period. Beyond the Cxcl16 
gene, it will be important to elucidate the genetic or epigenetic 
mechanisms by which the microbiota programs airway immune 
and structural cells as this appears to fine-tune the host response 
and affect not just the initial encounter with an environmental 
stimuli, such as an allergen or pathogen, but also the develop-
ment of long-term immunity.
It is emerging that microbial metabolites play a key role in 
regulating host physiology and immunity. Herein, we focus on 
the SCFAs acetic acid, butyric acid, and propanoic acid; however, 
it is noteworthy that other lipid derivatives are known to have 
immunomodulatory effects [reviewed in Ref. (121)]. SCFAs 
range in concentration from 50 to 100 mM in the gut and are 
the main metabolic end products from bacterial fermentation, 
particularly fermentation of dietary fiber. Hence, changes in 
dietary habits and factors that perturb the microbiota such as 
antibiotic use have a profound effect on SCFA production (122, 
123). In the gastrointestinal tract, SCFAs represent an impor-
tant energy source for both the local microbiota and intestinal 
epithelial cells. But, as well as being local substrates for energy 
production, it is now appreciated that SCFAs have diverse 
regulatory functions in host physiology and immunity affect-
ing both hematopoietic and non-hematopoietic cells. SCFAs 
function as histone deacetylase (HDAC) inhibitors and ligands, 
predominantly agonists, of G protein-coupled receptors (GPRs). 
The ability of SCFAs to inhibit HDACs generally promotes a 
tolerogenic, anti-inflammatory cell phenotype necessary for the 
maintenance of immune homeostasis, and this functional prop-
erty supports the concept that the gut microbiota can act as an 
epigenetic regulator of host physiology. Exposure of peripheral 
blood mononuclear cells or neutrophils to acetate, propionate, 
or butyrate suppresses NF-κB and downregulates the production 
of the pro-inflammatory cytokine TNF-α (124, 125). Subsequent 
studies revealed that these anti-inflammatory effects, mediated 
by HDAC inhibition, extend to both macrophages (126, 127) and 
DCs (128, 129). SCFAs can also modulate T cells, particularly 
Treg cells, through HDAC inhibition. For example, inhibition of 
HDAC9 increases FoxP3 expression, enhancing the suppressive 
function of Treg cells during homeostasis and in mouse models 
of colitis (130). Studies characterizing the ability of specific 
SCFAs to regulate the quality of the colonic Treg cell pool have 
shown that propionate and butyrate induce FoxP3 in an HDAC-
dependent manner, while acetate is less effective (15, 16). Of 
direct relevance to the function of SCFAs in asthma, Thorburn 
and colleagues explored the effect of modifying dietary fiber 
intake on the susceptibility of mice toward HDM-induced 
allergic airway inflammation (131). They began by comparing 
the gut microbiota of mice fed a high-fiber diet to mice fed 
an equicaloric control diet or a no-fiber diet for 3  weeks. As 
expected, the high-fiber diet significantly increased circulating 
levels of acetate and propionate, a phenotype that was associ-
ated with greater representation of Bacteroides, Clostridium, and 
Pandoraea spp. compared to mice fed the control diet. Mice fed 
on a no-fiber diet exhibited reduced (although not statistically 
TABLe 1 | Principal receptors for short-chain fatty acids.
Receptor Selective agonist (peC50) Reference
OLFR78 Propionic acid (3.0) Pluznick et al. (136)
GPR43 
(FFAR2)
Propanoic acid (3.0–4.9) Brown et al. (137), Le 
Poul et al. (138), Nilsson 
et al. (139), and Schmidt 
et al. (140)
Acetic acid (3.1–4.6)
Butyric acid (2.9–4.6)
1-Methylcyclopropanecarboxylic 
acid (2.6)
Trans-2-methylcrotonic acid (3.8)
GPR41 
(FFAR3)
Propanoic acid (3.9–5.7) Brown et al. (137), Le 
Poul et al. (138), Nilsson 
et al. (139), Schmidt et al. 
(140), and Xiong et al. 
(141)
Butyric acid (3.8–4.9)
1-Methylcyclopropanecarboxylic 
acid (3.9)
Acetic acid (2.8–3.9)
GPR109A β-d-Hydroxybutyric acid (3.1) Taggart et al. (142)
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significant) circulating SCFA levels and a greater abundance of 
Proteobacteria compared to the control diet group. When the 
effect of diet on HDM-induced allergic airways inflammation 
was assessed, mice fed a high-fiber diet or treated with acetate in 
the drinking were protected exhibiting reduced levels of airway 
eosinophils, type 2 cytokine production (IL-4, IL-5, and IL-13), 
serum IgE, and AHR. The no-fiber diet did not alter susceptibil-
ity to asthma in this model, consistent with the lack of effect 
on SCFA levels, which was unexpected given previous findings 
from another group (129). Because asthma typically develops in 
childhood, the authors next explored the effect of their dietary 
perturbations or acetate exposure during late-stage pregnancy 
(from E13) until weaning (3  weeks of age). The offspring of 
mice fed a high-fiber diet were protected from HDM-induced 
allergic airway inflammation whereas the offspring from mice 
fed a no-fiber diet developed disease to the same degree as mice 
fed the control diet. This latter finding is quite surprising given 
the importance of the gut microbiota and circulating SCFAs 
for immune development in early-life. A possible explana-
tion stems from the use of a high-dose of HDM which likely 
induced a maximal response in the control fiber diet fed mice, 
and hence this response could not be further elevated in the 
group fed on a no-fiber diet. Nevertheless, the effectiveness of 
the high-fiber maternal diet suggests that protective effects can 
occur in utero. In support of this, the investigators found that 
either acetate administration or high-fiber diet feeding until 
birth was sufficient to protect the offspring. This finding was 
further confirmed by litter swapping experiments, although 
the effect was less profound, for example, IL-5/13 production 
from lymph node T cell cultures was unchanged in the high-
fiber group, suggesting that some of the protective effects of the 
high-fiber diet occur postnatally. To translate their findings, the 
authors next explored whether human SCFA levels correlated 
with fiber intake in pregnant mothers and wheeze in their off-
spring. A significant but weak inverse correlation was observed 
between circulating maternal acetate levels and the percentage 
of infants requiring two or more general practitioner visits 
for wheeze and cough. Although viruses are a major cause of 
wheeze in infancy, the authors did not report which respiratory 
viruses were detected in these subjects. Importantly, it remains 
unknown whether lower SCFA levels, because of changes in 
maternal diet or other postnatal perturbations, increase the 
risk of respiratory viral illness, a major risk factor for asthma. 
Since the high-fiber diet conferred protection in utero and this 
persisted into adulthood the investigators hypothesized that 
this effect might be due to epigenetic regulation of Treg cells. 
They found that, through HDAC9 inhibition, acetate treatment 
endowed greater numbers of Treg cells and increased the sup-
pressive capacity of these cells. However, it remains to be tested 
whether a high-fiber diet  also mediates this effect specifically 
via acetate. The authors speculated that propionate played a less 
important role in their model, primarily because it was found at 
lower concentrations in the circulation; however, propionate is 
also a potent HDAC inhibitor in Treg cells, and other investiga-
tors have demonstrated a key role for propionate in protecting 
against HDM-induced asthma (129). Thus, the in utero effects 
of propionate remain ill-defined.
SHORT-CHAiN FATTY ACiDS AND 
ASTHMA
As well as their ability to inhibit HDAC activity, several studies 
have determined that SCFAs affect host immunity via engage-
ment of GPRs, including OLFR78, GPR43 (FFAR2), GPR41 
(FFAR3), and GPR109A (HCAR2). These receptors are expressed 
by numerous cell types, including immune cells and intestinal 
epithelial cells and are activated by various endogenous agonists 
including those summarized in Table 1. GPR43 signaling plays 
an important role in SCFA-induced neutrophil chemotaxis (124) 
and the expansion and suppressive function of Treg cells induced 
by SCFAs. GPR41 has aslo been implicated in supporting host 
immune function (132). In wild-type mice, but not in GPR41-
deficient mice, SCFAs arrest the maturation of pro-inflammatory 
DCs in a GPR41-dependent mechanism, thereby preventing the 
development of allergic airway inflammation in mice (129). It 
is noteworthy that a recent study reported mRNA and protein 
expression of GPR41 and GPR43 in bronchial epithelial cells 
(133), raising the possibility that SCFAs may regulate the airway 
epithelium, although functional studies remain to be performed. 
Studies in man have begun to test the hypothesis that decreases 
in gut microbial SCFAs antedate asthma development. In a recent 
high-profile study of Canadian infants, acetate levels in feces 
and serum were found to be lower in atopic/wheezy infants (at 
high risk of childhood asthma) compared to healthy controls at 
3 months (but not 12 months) of age (134). This was associated 
with reductions in specific bacterial genera: Faecalibacterium, 
Lachnospira, Veillonella, and Rothia in the feces. Similarly, in a 
cohort of Swedish infants, the composition and diversity of the 
gut microbiota during the first month of life was significantly 
lower and associated with asthma diagnosis at 7  years of age 
(135). Collectively, these data suggest that a lack of gut micro-
bial diversity in early-life has long-term consequences on host 
immunity. However, the direct cause of low infant SCFA levels 
in these studies remains unclear and may stem from a combina-
tion of factors affecting the maternal and neonatal microbiota. 
It will be important to address whether low SCFA levels are 
causally linked to vLRIs and asthma development and therein 
the underlying mechanisms. Additionally, whether poor diet and 
FigURe 1 | Schematic showing the timing of microbiota assembly 
with respect to bronchiolitis risk within the first year of life and how 
perturbations to the maternal or neonatal microbiota might prolong 
the window of susceptibility to bronchiolitis and increase overall risk.
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perturbations to the gut microbiota increase bronchiolitis risk as 
a consequence of a reduction in circulating SCFA levels remains 
to be determined; however, one might speculate this would have 
important long-term consequences for predisposition toward 
asthma and possibly other chronic respiratory diseases such as 
chronic obstructive pulmonary disease. In this regard, establish-
ing whether SCFAs enhance lung epithelial barrier integrity is 
likely to be of great importance. Given the accumulating data 
discussed in this review linking vLRIs and microbiota-associated 
perturbations in early-life it will be important to elucidate the 
biological mechanisms underlying these clinical observations. We 
propose that maternal and/or infant microbial dysbiosis increases 
and prolongs the window of bronchiolitis risk in infancy (see 
Figure 1); this may occur through functional aberrancy of the 
host response to initial RSV infection, leading to severe illness, 
and this alone may be sufficient to cause long-lasting changes 
to host immunity that predisposes to asthma in later life. In this 
proposed scenario, environmental factors that affect microbial 
colonization in the infant, such as maternal diet, cesarean delivery, 
transmission of microbial dysbiosis from the mother, maternal/
infant antibiotic use, breast-feeding, as well as others will impact 
on the production of microbial metabolites and as a consequence 
affect the development and function of immune cells (e.g., DCs 
and Tregs) and structural cells (e.g., AECs) that in turn, control 
RSV immunopathogenicity.
BReAST-FeeDiNg AND ASTHMA
As well as being the primary source of nutrition for the infant, 
breast milk contains immunomodulatory factors that affect the 
host immune response. The intestinal contents of breast-fed 
infants are acidic (pH 5.0), whereas those of non-breast fed infants 
is neutral (pH 7.1) (143). Milk oligosaccharides are the principal 
factor that support the growth of bifidobacteria (112) and hence 
may influence gastrointestinal and circulating SCFA levels in the 
infant. Thus, milk oligosaccharides likely serve as prebiotics to 
support the selective growth of “beneficial” bacteria, providing 
these commensals with a competitive advantage over potential 
pathogens. Milk oligosaccharides have also been postulated to 
exert direct anti-pathogenic and pro-tolerogenic roles in the 
intestine by acting as glycan receptor decoys for microbial adhe-
sion factors and preventing pathogen attachment. Additionally, 
they can modulate the balance between Th1/Th2 immunity and 
provide essential nutrients for brain development and cognition 
[for a detailed review, see Ref. (112)]. Breast milk also contains a 
variety of food borne and aeroallergens that are transferred to the 
infant and influence sensitization to these antigens. In an elegant 
study by Verhasselt and colleagues, transforming growth factor-β 
transferred in breast milk was shown to facilitate T cell tolerance, 
protecting the offspring from OVA/alum-induced allergic airways 
disease (144). Birth cohort studies demonstrate that non-breast-
fed infants are at greater risk of developing asthma (145–148), 
strongly implicating maternal factors in protecting against 
disease. Moreover, several epidemiological studies have linked a 
lack of breast-feeding to the severity of RSV infection (149–152), 
although this finding is not universal (153). Taken together, these 
studies demonstrate that breast milk represents a critical environ-
mental determinant of colonization and profoundly influences 
immune homeostasis and postnatal development. However, the 
specific breast-milk derivatives and the causal pathways relating 
these to protection against respiratory pathogens and allergic 
sensitization in early-life require further investigation.
THe MATeRNAL MiCROBiOTA AND 
iNFANT ReSPiRATORY HeALTH
The composition of the maternal intestinal microbiota and the 
infant intestinal microbiota has been shown to affect the risk of 
infant wheeze (88), although the underling mechanisms have 
remained elusive. In an elegant study designed to address whether 
transient colonization during gestation alone can affect immune 
cell development and immune responses in the offspring, de 
Agüero and colleagues inoculated pregnant GF mice during late 
gestation with a bioengineered strain of Escherichia coli (HA107) 
that is cleared from the intestine within 72 h (154). Interestingly, 
colonization with E. coli during late-gestation led to a more 
competent intestinal immune system in the offspring, including 
increases in type-3 ILCs and F4/80+ CD11c+ mononuclear cells. 
This more physiologically normal cellular phenotype attenuated 
the overt inflammatory response observed in GF mice in response 
to microbial molecules and penetration of intestinal pathogens. 
Importantly, the protective effect of gestational colonization was 
not restricted to the gastrointestinal tract as the investigators 
demonstrated improved orchestration of the immune response 
within the spleen following intraperitoneal LPS administration. 
These intriguing data, albeit from an experimental system, sug-
gest for the first time that the systemic immune responses of the 
offspring can be shaped by maternal gestational colonization 
alone. Whether similar processes operate to control the seeding 
of ILC subsets at other mucosal surfaces remain to be determined. 
The bidirectional signaling between type 2 ILCs and epithelial 
cells in the respiratory tract is important for tissue homeostasis 
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and repair (155), and so it will be important to learn whether 
the maternal microbiota can influence lung barrier immunity 
to respiratory pathogens and other stimuli. Mechanistically, de 
Agüero et  al. found that gestation-only colonization conferred 
protection in part through the generation of maternal antibod-
ies. However, maternal antibody transfer alone was not entirely 
sufficient to mediate the positive effects of gestational E. coli on 
immunity, rather it assisted in the transfer of bacterial metabolites 
including aryl hydrocarbon receptor ligands, known to drive ILC3 
expansion (156) and limit adult bacterial translocation across the 
intestinal epithelium. Consistent with the literature, the authors 
found that aryl hydrocarbon receptor ligand administration 
restored the levels of ILC3 in the gut, although other peripheral 
tissues were not assessed. The authors found no role for SCFAs, 
as exogenous administration of a butyrate, propionate and acetate 
mixture during pregnancy had no effect on the numbers of type-3 
ILCs and mononuclear cells in the offspring’s intestine, although 
the in utero effects of SCFAs on other aspects of immune respon-
siveness in the offspring was not assessed.
The influence of the maternal microbiota and provision of 
various constituents in the breast milk must now implicate an 
important role for the maternal diet in the early development 
and training of the offspring’s immune system. Of relevance, a 
recent prospective birth cohort study of >56,000 Argentinian 
children under 2 years of age examined maternal dietary pref-
erences and the impact on the children’s respiratory health (7). 
Of the 1,293 children who had a respiratory infection, >60% 
were infected with RSV, 22% with human RV, and 4% with 
influenza, highlighting RSV as the most significant pathogen 
affecting infant respiratory health. Intriguingly, when the 
maternal diet was high in carbohydrates and low in fruit and 
vegetables, this had profound effects on RSV-associated disease 
in the offspring, increasing the odds ratio of developing severe 
hypoxemia and life-threatening disease. The mechanisms 
underpinning this association remain unclear but might relate 
to alterations in the maternal microbiome and possibly fetal 
development. Most notably, it will be important to ascertain 
the relative contribution of elevated carbohydrate intake 
versus low fiber intake on disease outcome, i.e., was severe 
RSV-bronchiolitis caused by a lack of fiber and the resulting 
decrease immune cell-supportive microbial metabolites (e.g., 
SCFAs) or refined sugars promoting the outgrowth of bacterial 
pathogens or a combination of both.
Understanding the processes by which maternal diet influences 
asthma susceptibility is of crucial importance. As discussed above, 
feeding pregnant mice a high-fiber diet or SCFA-supplementation 
via the drinking water suppresses the development of allergic air-
way inflammation by increasing the suppressive activity of Treg 
cells via a HDAC9-dependent mechanism (131). Importantly, the 
suppressive effects of the maternal high-fiber diet were passed on 
to the offspring, indicating the epigenetic potential of SCFAs in 
the development of the immune system and in protection from 
asthma. In addition, feeding adult mice with a high-fiber diet or 
treating with exogenous propionate is protective against HDM-
induced airway inflammation (129). Collectively, these data high-
light the potential for modulating SCFA levels as a preventative 
strategy to protect against RSV-bronchiolitis and asthma.
HARNeSSiNg THe MiCROBiOTA TO 
PReveNT AND/OR TReAT 
BRONCHiOLiTiS
Immunological tolerance is an important goal for the prevention 
of asthma and allergic diseases and thus mechanisms to promote 
a healthy intestinal microbiota are under investigation (157–159). 
A new wave of Th2-targeted biologics has recently been approved 
for asthma (160); however, we speculate that this approach is 
unlikely to reverse the aberrantly programmed epithelium and/or 
immune response (61, 161). Microbial metabolites and beneficial 
commensals shape the immune response in early-life, suggesting 
that supplementing or mimicking these factors may represent 
a new approach for disease prevention. Of greater interest will 
be to determine whether such strategies can alter the course of 
disease or even reverse established asthma, a far greater challenge 
should the epigenetic programming of immune and structural 
cells already be set to an aberrant phenotype.
Prebiotics, Probiotics, and Synbiotics
In the 2013 update to the Cochrane Review, a meta-analysis 
was performed on two studies examining the effect of prebiotic 
treatment on asthma outcomes (162, 163). In the first study, 
Moro et al. reported a significant reduction in asthma outcome 
following treatment of 102 infants “at risk” of allergies with 
galacto-oligosaccharides and fructo-oligosaccharides (0.8  g/
dL) compared to 104 treated with placebo. In the second report, 
Westerbeek et al. treated similarly high-risk infants with acidic 
and neutral oligosaccharides (20/80%; 1.2  g/L) and found no 
significant difference in asthma outcomes. The meta-analysis 
reported no significant effect of the prebiotic treatment overall, 
although significant heterogeneity was found between these 
reports. One possible explanation for the discrepant findings is 
the prebiotic employed and their respective effects on the infant 
microbiota. Although both of these oligosaccharides have been 
shown to increase bifidobacterial growth, their impact on other 
potential beneficial gut microbes remains to be fully deter-
mined. Moreover, in both studies prebiotic treatment began at 
approximately 6 months of age though microbial dysbiosis has 
been reported at 3 months of age in infants that go on to develop 
asthma in later childhood (134) and may commence even earlier, 
as described above. Thus, an earlier intervention that positively 
affects the assembly of the host microbiota is likely to be more 
successful. The use of prebiotics as therapeutics and preventatives 
is in its infancy; however, the nature and timing of these prebiotic 
strategies will improve as our knowledge of the composition of 
the human microbiota and its functional effects on host physiol-
ogy and immune development increases.
A meta-analysis of four studies investigating effect of pro-
biotics on established asthma found little or no benefit (164). 
However, the authors highlighted that marked heterogeneity 
among the studies made direct statistical comparisons difficult. 
This meta-analysis did not include a subsequently published 
study by Chen et  al. (165). In this double-blinded, placebo-
controlled trial, oral administration of Lactobacillus gasseri over 
a 5-week period was found to be effective in reducing bronchial 
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hyperreactivity, improving lung function, and reducing day-time 
asthma symptoms in school-age (6–12  years) children with 
allergic asthma (165). L. gasseri treatment decreased the produc-
tion of pro-inflammatory cytokines (e.g., TNF-α, IL-13) from 
phytohemagglutinin- or Derp1-stimulated peripheral blood 
mononuclear cells, although unfortunately Treg cells were not 
measured as part of the study. Similarly, oral inoculation with 
Lactobacillus rhamnosus or Lactobacillus reuteri protected against 
allergic airway inflammation in mice by increasing the number 
and function of Treg cells in the systemic circulation (158, 166, 
167). In another study, oral administration of the bacterial 
preparation OM-85BV ameliorated the hallmark features of 
allergic asthma in mice (IgE, airway eosinophilia, and AHR) via 
the induction of gastrointestinal Treg cells. These suppressive 
Treg cells trafficked to the lung and inhibited airway mucosal 
CD86+ DCs, blunting the type 2 inflammatory response (168). 
In the context of allergic disease, few studies have evaluated the 
clinical efficacy of a probiotic in combination with prebiotic 
oligosaccharides (known as a synbiotic). One randomized trial 
examined 29 adults with asthma and HDM allergy treated with 
synbiotics (Bifidobacterium breve M-16V and a mixture of 90% 
short-chain galacto- oligosaccharides and 10% long-chain fructo-
oligosaccharides) or placebo for 4 weeks followed by a bronchial 
challenge with HDM allergen (169). Although peak expiratory 
flow and systemic Th2 cytokines were reduced in the synbiotic-
treated group, there was no effect on sputum eosinophilia or 
neutrophilia. These preliminary findings require replication by 
other investigators.
Interestingly, pre-treatment of mice with L. rhamnosus has 
also been shown to protect against pathogenic type 2 inflamma-
tion during RSV infection. This was associated with an increase 
in the production of IFN-β, IFN-γ, and IL-10 as well as both 
CD103+ and CD11b high DCs, although Treg cells were not 
assessed (170). A number of clinical studies have demonstrated 
the efficacy of prebiotic (171, 172) or probiotic interventions 
(172–175) for the treatment of respiratory viral infections. For 
example, in a randomized, placebo-controlled, double-blind trial, 
Luoto et  al. investigated the efficacy of galacto-oligosaccharide 
and polydextrose mixture (1:1), known to promote bifidobacteria 
and lactobacilli, and the probiotic L. rhamnosus in a cohort of 
preterm infants in Finland. Strikingly, both the prebiotic mixture 
of galacto-oligosaccharide and polydextrose and L. rhamnosus 
significantly reduced the incidence of RV-induced episodes, 
which was the cause of the infection in 80% of the infants in the 
cohort. Although RSV-associated vLRIs were not affected by 
either treatment, the RSV group represented only a small propor-
tion of the cohort, and therefore, larger studies will be required 
to determine the effect of synbiotics on RSV-bronchiolitis risk. 
Moreover, it will be important for longer term studies to assess 
whether decreasing the severity of vLRI in these children can 
protect from the development of asthma in later-life.
SCFAs and SCFA Mimetics
Human epidemiology and experimental studies in preclinical 
models of asthma suggest that dietary fiber protects against 
asthma risk by increasing fecal and systemic levels of SCFA. 
Accordingly, mimicking the anti-inflammatory effects of SCFAs 
pharmacologically is an attractive approach therapeutically. The 
anti-inflammatory effects of acetate and propionate have been 
ascribed to HDAC inhibition and the activation of GPR41 and/or 
GPR43 signaling, and as described above, these pathways amelio-
rate allergic airway inflammation in mice by increasing the func-
tion of Treg cells or by dampening pro-inflammatory DCs (15, 129, 
131, 176). Although GPR109a, the primary receptor for butyrate, 
is reported to be expressed in lung tissue, its cellular distribution 
and function in the lung remains unclear (177). An additional 
target of SCFAs may be the bronchial epithelium, which expresses 
both GPR41 and GPR43, although increases in SCFA levels and 
GRP41 expression are proposed to be deleterious in the context of 
cystic fibrosis (133). Notably, recent pharmacological studies have 
reported development of small molecules with greater selectiv-
ity than endogenous SCFAs (140, 178), although increasing the 
potency of these compounds has yet to be achieved. Moreover, the 
efficacy of this current generation of molecules in animal models 
of asthma remains unexplored. Therefore, in addition to further 
elucidating the biology of these receptors, it will be important for 
drug discovery programs to continue to improve the selectivity and 
potency of synthetic agonists and to test their efficacy in clinically 
relevant models of viral bronchiolitis and asthma. pDCs present 
an attractive target for the prevention of severe RSV-bronchiolitis 
and asthma due to their capacity to produce vast amounts of type 
I IFN via engagement of TLRs (e.g., TLR7) and promote Treg cell 
expansion (179). We have shown that infection with pneumonia 
virus of mice (58), a mouse-specific Pneumovirus of the same 
genus as RSV, predisposes to severe bronchiolitis in Tlr7-deficient 
mice, while the adoptive transfer of Tlr7-sufficient pDC to Tlr7-
deficient mice confers protection, implicating a critical role for 
TLR7 on pDCs. Moreover, secondary infection of TLR7-deficient 
mice induced the cardinal features of asthma, including AHR, 
airway remodeling (e.g., smooth muscle hyperplasia), and airway 
inflammation (180). Collectively, these findings suggest that the 
nexus between severe bronchiolitis and subsequent asthma is 
underpinned by perturbations to the pDC compartment (61). 
Hence, it will be important to determine whether SCFAs or SCFA 
mimetics are able to modulate pDC function.
CONCLUSiON
Illuminating epidemiological, clinical, and preclinical studies 
suggest that the microbiome plays a critical role in protecting 
against asthma and allergies, particularly in early-life. Despite 
the fact that RSV-bronchiolitis predominantly affects infants 
under 6 months of age, the influence of gut microbial coloniza-
tion and microbial metabolites on susceptibility to severe RSV-
bronchiolitis has yet to be investigated. Programming of airway 
immune and structural cells likely occurs during this window of 
susceptibility and will have long-term consequences for suscepti-
bility toward asthma-inducing stimuli. Identifying the molecular 
pathways that link the gut microbiota and the development of 
lung mucosal immunity has the potential to identify new thera-
peutic targets for the treatment of RSV-bronchiolitis. In view of 
the strong link between severe RSV-bronchiolitis and subsequent 
asthma, such a strategy has the potential to ameliorate the current 
high rates of allergic asthma in developed nations.
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